03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
15:31 , May 25, 2018 |  BC Week In Review  |  Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic...
00:38 , Jan 27, 2018 |  BC Extra  |  Company News

FDA to review its pediatric exclusivity decision for Amgen's Sensipar

A federal judge ordered FDA to address whether its decision to grant pediatric exclusivity to Ortho Tri-Cyclen norgestimate/ethinyl estradiol from the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) is consistent with its decision...
18:36 , Jan 11, 2018 |  BC Innovations  |  Emerging Company Profile

Next, after T cells

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T...
01:22 , Jan 4, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models An allogeneic macaque model of HSCT-associated GvHD could be used to screen for therapies. Transplant of HSCs between pairs of allogeneic cynomolgus macaques that harbored matching major histocompatibility complex (MHC) alleles at...
23:13 , Sep 15, 2017 |  BC Extra  |  Financial News

Bavarian Nordic plummets on Phase III CRPC failure of ProstVac

Bavarian Nordic A/S (CSE:BAVA) sank DKK213.50 (48%) to DKK230, losing DKK6.8 billion ($1.1 billion) in market cap, on Friday after an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer (CRPC) based on a preplanned interim analysis. The primary...
23:17 , Sep 14, 2017 |  BC Extra  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC trial of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer based on a preplanned interim analysis. The primary endpoint...
02:27 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

FDA approves Orencia for psoriatic arthritis

FDA approved Orencia abatacept from Bristol-Myers Squibb Co. (NYSE:BMY) to treat psoriatic arthritis. The product is a CTLA-4 (CD152)-Ig fusion protein available in both IV and subcutaneous formulations. It is already approved in the U.S....